by Jason Heaviland | Mar 2, 2026
Exposomics Measuring Chemical Drivers of Human Disease Panome Bio’s Exposomics platform enables comprehensive measurement of chemical exposures that drive human disease. Using integrated discovery (32,000+ compounds) and targeted profiling (235 priority chemicals), we...
by Jason Heaviland | Mar 2, 2026
Chemical Exposure Profiling of Alzheimer’s Patients This webinar presents a comprehensive overview of chemical exposure profiling in Alzheimer’s patients using Panome Bio’s Targeted Exposomics™ and Discovery Exposomics™ platforms. Learn how quantitative exposure...
by Jason Heaviland | Feb 27, 2026
This data report showcases Discovery Exposomics results from a study examining chemical exposure patterns associated with Alzheimer’s disease. Using Panome Bio’s expansive database of more than 32,000 environmental and exposure-related compounds, the analysis provides...
by Jason Heaviland | Feb 27, 2026
This data report presents Targeted Exposomics findings from a study investigating chemical exposure patterns linked to Alzheimer’s disease. Using highly sensitive quantitative analysis, the report outlines exposure-related biomarkers, altered chemical profiles, and...
by Jason Heaviland | Feb 27, 2026 | Uncategorized
For 20 years, genomics has promised precision medicine. And it delivered. For rare diseases and select cancers. But for most chronic conditions?
Genetics explains only a fraction of risk. Type 2 diabetes. Alzheimer’s disease. Autoimmune disorders. Metabolic syndrome....
